Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 1997

View Archived Issues

Company Profile: Aastrom Biosciences

Immunogen terminates Oncolysin development

Novel antihyperlipidemic agent from Shionogi in phase II

Maxim notified of patent allowance for MaxVax technology

Grelan characterizes candidate for diabetic complications

Phase II trial of Leukine as adjuvant for advanced melanoma

Hirosaki University researchers present novel class Ib antiarrhythmic

FDA clears rapid test for myocardial damage

Mitsui Toatsu reveals orally active antiplatelet agent

Tumor-suppressing gene identified by scientists at Northwest Hospital

Highly potent and selective ETA antagonist from Tanabe Seiyaku

Meiji Seika's new orally active gpIIb/IIIa antagonist

Agent for atopic dermatitis reported by Terumo

Enzo receives notice of allowance of Japanese patent for antisense technology

Sumitomo presents new Na+/H+-exchange inhibitor

International sepsis forum established with funding from Bayer

SA-7060: a dual NEP and ACE inhibitor from Santen

Promising PHP phase I/II results reported

Dermagraft-TC cleared for marketing

Fujisawa selects orally active fibrinogen antagonist for clinical studies

Peptech awarded grant for development of GMDP

Oncogene Science granted rights to Dow's compound library

Collaborative effort culminates in clinical trials for HIV gene therapy using ribozymes

Antex Biologics reports on Campylobacter vaccine trial

Glaxo Wellcome licenses HSV vaccine

Oncogene Science and Sepracor enter drug discovery collaboration

Collaboration formed to identify chronic anemia treatment

Gensia Sicor selects Brevibloc distributor for U.K. and Ireland

Amylin and J&J broaden collaboration

Sugen's psoriasis treatment enters clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...